AR060042A1 - Nanoparticulas que comprenden un inhibidor de tirosina quinasa del receptor de pdgf - Google Patents

Nanoparticulas que comprenden un inhibidor de tirosina quinasa del receptor de pdgf

Info

Publication number
AR060042A1
AR060042A1 ARP070101158A ARP070101158A AR060042A1 AR 060042 A1 AR060042 A1 AR 060042A1 AR P070101158 A ARP070101158 A AR P070101158A AR P070101158 A ARP070101158 A AR P070101158A AR 060042 A1 AR060042 A1 AR 060042A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
free
substituted
amino
nanoparticles
Prior art date
Application number
ARP070101158A
Other languages
English (en)
Original Assignee
Univ Kyushu Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38122006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kyushu Nat Univ Corp filed Critical Univ Kyushu Nat Univ Corp
Publication of AR060042A1 publication Critical patent/AR060042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Nanopartículas que comprenden un inhibidor de tirosina quinasa del receptor PDGF, donde el inhibidor de tirosina quinasa del receptor PDGF tiene una solubilidad en agua a 20°C de entre alrededor de 2,5 g/100 ml y 250 g/100 ml, y es un derivado de N- fenil-2-pirimidin-amina de la formula (1), donde: R1 es 4-pirazinilo; 1-metil-1H-pirrolilo; fenilo sustituido con amino o amino alquilo inferior, donde el grupo amino en cada caso está libre, alquilado o acilado; 1H-indolilo o 1H-imidazolilo enlazado en un átomo de carbono de anillo de cinco miembros; o piridilo no sustituido o sustituido con alquilo inferior, enlazado en un átomo de carbono de anillo, y no sustituido o sustituido en el átomo de nitrogeno con oxígeno; R2 y R3 son, de manera independiente entre sí, hidrogeno o alquilo inferior; uno o dos de los radicales R4, R5, R6, R7 y R8 son nitro, alcoxi inferior sustituido con fluor, o un radical de formula -N(R9)-C(=X)-(Y)n-R10, donde: R9 es hidrogeno o alquilo inferior; X es oxo, tio imino, N-alquilo inferior-imino, hidroxiimino, u O-alquilo inferior-hidroxiimino; Y es oxígeno o el grupo NH; n es 0 o 1; y R10 es un radical alifático que tiene por lo menos 5 átomos de carbono; o un radical aromático, aromático- alifático, cicloalifático, cicloalifático-alifático, heterocíclico o heterocíclico-alifático; y los radicales restantes R4, R5, R6, R7 y R8 son, de manera independiente entre sí, hidrogeno, alquilo inferior no sustituido o sustituido con amino libre o alquilado, piperazinilo, piperidinilo, pirrolidinilo o con morfolinilo, o alcanoílo inferior, trifluorometilo, hidroxi libre, eterificado o esterificado, amino libre, alquilado o acilado, o carboxi libre o esterificado; o una sal de dicho compuesto que tiene por lo menos un grupo formador de sales; un proceso para su preparacion; sus composiciones farmacéuticas; y el uso de nanopartículas de acuerdo con cualquiera de las reivindicaciones 1 a 9, en la elaboracion de un producto farmacéutico para la estabilizacion de placas vulnerables en los vasos sanguíneos de un sujeto que necesita dicha estabilizacion, para la prevencion o el tratamiento de restenosis en pacientes diabéticos, o para la prevencion o reduccion de la disfuncion de acceso vascular asociada con la insercion o reparacion de una derivacion, fístula o un catéter permanentes, en un sujeto que lo necesita. Reivindicacion 4: Nanopartículas de acuerdo con la reivindicacion 3, donde el derivado de N- fenil-2-pirimidin-amina de formula (1) es N-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina (Imatinib).
ARP070101158A 2006-03-24 2007-03-21 Nanoparticulas que comprenden un inhibidor de tirosina quinasa del receptor de pdgf AR060042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78557606P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
AR060042A1 true AR060042A1 (es) 2008-05-21

Family

ID=38122006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101158A AR060042A1 (es) 2006-03-24 2007-03-21 Nanoparticulas que comprenden un inhibidor de tirosina quinasa del receptor de pdgf

Country Status (11)

Country Link
US (1) US20090136579A1 (es)
JP (1) JP2007254452A (es)
KR (1) KR20070096729A (es)
AR (1) AR060042A1 (es)
BR (1) BRPI0602338A (es)
CA (1) CA2550702A1 (es)
CL (1) CL2007000781A1 (es)
MX (1) MXPA06007070A (es)
PE (1) PE20071337A1 (es)
TW (1) TW200815053A (es)
WO (1) WO2007119601A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042803A1 (en) 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2010101240A1 (ja) * 2009-03-06 2010-09-10 国立大学法人岡山大学 生分解性多孔質中空微粒子、その製造方法および用途
RU2469729C1 (ru) * 2011-08-26 2012-12-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт кардиологии Сибирского отделения РАМН Средство для деструктуризации атеросклеротических образований, формирующихся на стенках кровеносных сосудов
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US11007276B2 (en) 2016-01-29 2021-05-18 National University Corporation Hokkaido University Intracellular substance transport system and use thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
AU2020274521A1 (en) 2019-05-16 2021-12-16 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
JP2023550407A (ja) * 2020-11-17 2023-12-01 ユナイテッド セラピューティクス コーポレイション 肺高血圧向けの吸入式イマチニブ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
CN1309422C (zh) * 2005-08-29 2007-04-11 江征平 聚合物纳米粒子和药物胶囊及制备
US20070065477A1 (en) * 2005-09-12 2007-03-22 Conor Medsystems, Inc. Composition, system, and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility

Also Published As

Publication number Publication date
PE20071337A1 (es) 2008-01-08
CL2007000781A1 (es) 2008-03-14
KR20070096729A (ko) 2007-10-02
TW200815053A (en) 2008-04-01
CA2550702A1 (en) 2007-09-24
US20090136579A1 (en) 2009-05-28
MXPA06007070A (es) 2007-09-24
WO2007119601A3 (en) 2008-02-21
WO2007119601A2 (en) 2007-10-25
JP2007254452A (ja) 2007-10-04
BRPI0602338A (pt) 2007-12-11

Similar Documents

Publication Publication Date Title
AR060042A1 (es) Nanoparticulas que comprenden un inhibidor de tirosina quinasa del receptor de pdgf
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ECSP066298A (es) Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3)
BR9913654A (pt) Inibidores de p-38alfa quinase
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
SE0202463D0 (sv) Novel compounds
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
AR040390A1 (es) Inhibidores de quinasas de tirosina
NO20080963L (no) Piperidinyl-substiuerte isokinolinderivater som Rho-kinaseinhibitorer
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
AR045587A1 (es) Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
IL150481A0 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
AR043063A1 (es) Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
DE60034961D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
CA2401812A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
CA2439268A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
MX2009003283A (es) Nuevos derivados imidazolonas, su preparacion como medicamentos, composiciones farmaceuticas y uso como inhibidores de proteinas quinasas, principalmente cdc7.

Legal Events

Date Code Title Description
FB Suspension of granting procedure